MedTrace Logo

Parathyroidectomy in Endstage Renal Disease

NCT00745719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2020-08-05

No results posted yet for this study

Summary

To test the hypothesis that total parathyroidectomy retards cardiovascular calcification, improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in end-stage renal disease patients on maintenance dialysis.

Conditions

  • Endstage Renal Disease

Interventions

PROCEDURE

parathyroidectomy

total parathyroidectomy with forearm autografting

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Angela YM Wang, MD, PhD · Queen Mary Hospital, University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2011-09-30
Completion
2012-01-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745719 on ClinicalTrials.gov